Latest Biotech News

Illumina appointed Eric Green, former director of the National Human Genome Research Institute, as its chief medical officer effective Feb. 2. Green succeeds a vacancy in Illumina’s medical...

Alveus Therapeutics emerged with a $159.8–$160 million Series A to advance a Phase‑2 ready obesity candidate that targets the same two pathways as Amgen’s MariTide, with claims of potential dosing...

Eli Lilly agreed to acquire San Diego-based Ventyx Biosciences in a roughly $1.2 billion all-cash deal to gain control of clinical-stage NLRP3 inhibitors. Lilly priced the transaction at $14 per...

Aktis Oncology completed a $318 million Nasdaq initial public offering, marking biotech’s first IPO of 2026. The Boston-based radiopharmaceutical developer priced 17.65 million shares at $18...

Parabilis Medicines raised $305 million in a Series F financing to push its Helicon platform and lead candidate, zolucatetide, toward later-stage testing. The round, led by RA Capital, Fidelity...

EpiBiologics closed a $107 million Series B to advance its EpiTAC platform and first-in-human candidate EPI-326, a bispecific antibody designed to degrade tumor-surface proteins such as mutant...

GSK and Ionis announced positive topline results from two pivotal Phase 3 studies (B‑Well 1 and B‑Well 2) testing bepirovirsen, an antisense oligonucleotide for chronic hepatitis B. The programs...

Immuneering updated Phase IIa data showing its oral MEK inhibitor atebimetinib, given with modified gemcitabine/nab‑paclitaxel chemotherapy, was associated with a 64% overall survival rate at 12...

OpenAI launched ChatGPT for Healthcare, a product that expands the company’s footprint into hospitals and health systems by offering a dedicated, clinician-facing workflow for health conversations...

Alveus Therapeutics launched with about $160 million in Series A funding to advance a Phase‑2 ready dual-agonist obesity candidate that targets the same two pathways as Amgen’s MariTide, while...

Researchers at the University of British Columbia reported a reproducible method to produce human helper (CD4+) T cells from pluripotent stem cells, a longstanding manufacturing bottleneck for...

Storm Therapeutics announced a strategic collaboration with Alida Biosciences to use AlidaBio’s EpiPlex/EpiScout platforms to quantify transcript‑specific m6A RNA modifications in clinical samples...

Eli Lilly agreed to acquire San Diego biotech Ventyx Biosciences for roughly $1.2 billion in cash, targeting Ventyx’s clinical-stage NLRP3 inhibitor programs. Lilly said the buy adds oral NLRP3...

Parabilis Medicines closed a $305 million Series F to accelerate development of its Helicon peptide platform and lead candidate zolucatetide, which targets intracellular beta‑catenin pathways. The...

EpiBiologics raised $107 million in a Series B co-led by GV and J&J’s venture arm to advance its surface protein-targeting degraders (EpiTACs) toward human testing in lung and head-and-neck...

Spatial transcriptomics company Vizgen closed a $48 million financing led by Arch Venture Partners, M Ventures and Northpond to accelerate commercial growth and push toward profitability. CEO Rob...

Guardant Health secured Tricare coverage for Shield, its blood-based colorectal cancer screening test, making the FDA‑cleared assay available with no copay to active-duty service members and...

Storm Therapeutics announced a strategic partnership with Alida Biosciences to analyze transcript‑specific m6A RNA modifications in clinical samples from patients treated with Storm’s METTL3...

GSK and Ionis announced positive topline results from pivotal B‑Well 1 and B‑Well 2 Phase 3 studies of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B that aims for a functional...

Gordian Bio entered a collaboration with Pfizer to deploy Gordian’s in vivo mosaic screening platform in visceral adipose tissue to discover and prioritize obesity targets directly in...